Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non‐Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study

Read full text Summarise with VIRAT
Authors: Toshiaki Takakura, Ryota Shibaki, Atsushi Washioka, Yusuke Murakami, Yuhei Harutani, Hiroaki Akamatsu, Nobuyuki Yamamoto
Cited by: 0
References: 17

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: The addition of immune checkpoint inhibitor (ICI) to platinum-based chemotherapy has improved outcomes in patients with advanced non-small cell lung cancer (NSCLC). However, evidence on the efficacy of adding ICI to platinum retreatment in patients who relapse after perioperative platinum-based chemotherapy remains limited. METHODS: We retrospectively analyzed patients with recurrent NSCLC following perioperative platinum-based chemotherapy. Patients were categorized into either the "chemo group," who received platinum retreatment without ICI, or the "ICI-chemo group," who received platinum retreatment with ICI. The primary endpoint was progression-free survival in patients treated with ICI. RESULTS: Among 124 patients who received perioperative platinum therapy and surgery, 31 underwent platinum retreatment: 17 in the chemo group and 14 in the ICI-chemo group. PFS was significantly longer in the ICI-chemo group than in the chemo group (15.4 vs. 5.9 months; log-rank p = 0.023; HR 0.40, 95% CI, 0.18-0.90). Among patients with PD-L1 ≥ 50%, the ICI-chemo group showed a greater trend toward longer PFS compared with the chemo group (16.9 vs. 4.0 months; HR 0.11, 95% CI, 0.01-1.05). CONCLUSIONS: Adding ICI to platinum retreatment may be an effective option for patients with NSCLC who relapse after perioperative chemotherapy, particularly in those with PD-L1 expression ≥ 50%.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations

Publication details

Journal / source
Thoracic Cancer
Volume
17
Issue
7
Pages
e70269–e70269
Publication date
30 March 2026
Language
EN